Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Development of Blood Vessels01:07

Development of Blood Vessels

The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways.

Nature communications·2025
Same author

Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade.

Cell reports. Medicine·2025
Same author

Immunological Tolerance to Luciferase and Fluorescent Proteins Using Tol Mice Enables Development of Improved Tumor Models for Investigating Immunity and Metastasis.

Cancer research·2025
Same author

Adenosine diphosphate stimulates VEGF-independent choroidal endothelial cell proliferation: A potential escape from anti-VEGF therapy.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

Metronomic chemotherapy and drug repurposing: Two sides of an oncology coin to reduce host and financial toxicity.

Cancer letters·2025

関連する実験動画

Updated: Jun 25, 2026

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber
09:55

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber

Published on: May 30, 2016

治療目標としての血管新生

Napoleone Ferrara1, Robert S Kerbel

  • 1Genentech, 1 DNA Way, South San Francisco, California 94080, USA. nf@gene.com

Nature
|December 16, 2005
PubMed
まとめ

血管新生を阻害することは,がんと年齢関連の黄斑変性障害の治療に有望な可能性を秘めています. 血管形態変異のさらなる理解は,心臓血管医学における治療的血管生成の進歩に不可欠です.

科学分野:

  • バイオメディカルサイエンスの科学
  • 心血管医学は,心血管医学である.
  • 腫瘍学 腫瘍学

背景:

  • 新しい血管の形成である血管新生は,生理学的および病理学的条件の両方で重要なプロセスです.
  • 血管新生を阻害することは,がんおよび年齢関連の黄斑変性に対する検証された治療戦略です.
  • 治療的血管新生は,血栓性疾患の治療のために血管の成長を促進することを目的としています.

研究 の 目的:

  • 血管新生抑制療法における進歩を要約する.
  • 治療的な血管新生の可能性を強調する.
  • 血管形態変生に関するさらなる研究の必要性を特定する.

主な方法:

  • 血管新生抑制薬の開発における最近の進歩のレビュー.
  • 承認された抗血管新生剤の分析.
  • 血管形態変異の基礎となるメカニズムについての議論.

主要な成果:

  • 血管新生抑制治療の開発において,著しい進展がみられた.
  • いくつかの抗血管新生剤は,規制当局の承認を受けています.
  • 血管形態変異の理解は,新しい治療法の開発の鍵です.

さらに関連する動画

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

Simple and Effective Procedure for Hemostasis in Mouse Arteries
05:34

Simple and Effective Procedure for Hemostasis in Mouse Arteries

Published on: November 28, 2025

関連する実験動画

Last Updated: Jun 25, 2026

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber
09:55

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber

Published on: May 30, 2016

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

Simple and Effective Procedure for Hemostasis in Mouse Arteries
05:34

Simple and Effective Procedure for Hemostasis in Mouse Arteries

Published on: November 28, 2025

結論:

  • 血管新生を阻害することは,特定の疾患を治療するための成功した戦略です.
  • 治療的血管新生は,心臓血管医学にとって有望な未来を示しています.
  • 血管形成の基本的メカニズムに関する継続的な研究は不可欠です.